Vakrangee Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: December 10, 2025, 10:30 pm

Competitors of Vakrangee Ltd

All Competitor Stocks of Vakrangee Ltd

Quarterly Result

Last Updated: August 1, 2025, 9:35 am

Below is a detailed analysis of the quarterly data for Vakrangee Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 68.84 Cr.. The value appears strong and on an upward trend. It has increased from 63.18 Cr. (Mar 2025) to 68.84 Cr., marking an increase of 5.66 Cr..
• For Expenses, as of Jun 2025, the value is 61.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 56.35 Cr. (Mar 2025) to 61.02 Cr., marking an increase of 4.67 Cr..
• For Operating Profit, as of Jun 2025, the value is 7.82 Cr.. The value appears strong and on an upward trend. It has increased from 6.83 Cr. (Mar 2025) to 7.82 Cr., marking an increase of 0.99 Cr..
• For OPM %, as of Jun 2025, the value is 11.36%. The value appears strong and on an upward trend. It has increased from 10.81% (Mar 2025) to 11.36%, marking an increase of 0.55%.
• For Other Income, as of Jun 2025, the value is 1.51 Cr.. The value appears to be declining and may need further review. It has decreased from 1.55 Cr. (Mar 2025) to 1.51 Cr., marking a decrease of 0.04 Cr..
• For Interest, as of Jun 2025, the value is 0.36 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.40 Cr. (Mar 2025) to 0.36 Cr., marking a decrease of 0.04 Cr..
• For Depreciation, as of Jun 2025, the value is 4.30 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.29 Cr. (Mar 2025) to 4.30 Cr., marking an increase of 0.01 Cr..
• For Profit before tax, as of Jun 2025, the value is 4.67 Cr.. The value appears strong and on an upward trend. It has increased from 3.69 Cr. (Mar 2025) to 4.67 Cr., marking an increase of 0.98 Cr..
• For Tax %, as of Jun 2025, the value is 28.91%. The value appears to be improving (decreasing) as expected. It has decreased from 31.71% (Mar 2025) to 28.91%, marking a decrease of 2.80%.
• For Net Profit, as of Jun 2025, the value is 3.32 Cr.. The value appears strong and on an upward trend. It has increased from 2.52 Cr. (Mar 2025) to 3.32 Cr., marking an increase of 0.80 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.03. The value appears strong and on an upward trend. It has increased from 0.02 (Mar 2025) to 0.03, marking an increase of 0.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:11 am

Growth

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: December 4, 2025, 2:11 am

Below is a detailed analysis of the balance sheet data for Vakrangee Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 108.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 108.00 Cr..
• For Reserves, as of Sep 2025, the value is 100.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Mar 2025) to 100.00 Cr., marking an increase of 6.00 Cr..
• For Borrowings, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 130.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 102.00 Cr. (Mar 2025) to 130.00 Cr., marking an increase of 28.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 343.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 309.00 Cr. (Mar 2025) to 343.00 Cr., marking an increase of 34.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 119.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Mar 2025) to 119.00 Cr., marking an increase of 9.00 Cr..
• For CWIP, as of Sep 2025, the value is 9.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Mar 2025) to 9.00 Cr., marking a decrease of 8.00 Cr..
• For Investments, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 1.00 Cr..
• For Other Assets, as of Sep 2025, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 177.00 Cr. (Mar 2025) to 210.00 Cr., marking an increase of 33.00 Cr..
• For Total Assets, as of Sep 2025, the value is 343.00 Cr.. The value appears strong and on an upward trend. It has increased from 309.00 Cr. (Mar 2025) to 343.00 Cr., marking an increase of 34.00 Cr..

Notably, the Reserves (100.00 Cr.) exceed the Borrowings (4.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Vakrangee Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
• For Diluted EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
• For Cash EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 3. It has increased from 0.18 (Mar 24) to 0.21, marking an increase of 0.03.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.64. It has increased from 1.14 (Mar 24) to 1.64, marking an increase of 0.50.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.64. It has increased from 1.14 (Mar 24) to 1.64, marking an increase of 0.50.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 2.35. It has increased from 2.01 (Mar 24) to 2.35, marking an increase of 0.34.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 2. It has decreased from 0.27 (Mar 24) to 0.25, marking a decrease of 0.02.
• For PBIT / Share (Rs.), as of Mar 25, the value is 0.10. This value is within the healthy range. It has decreased from 0.12 (Mar 24) to 0.10, marking a decrease of 0.02.
• For PBT / Share (Rs.), as of Mar 25, the value is 0.08. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.08, marking an increase of 0.03.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 2. It has increased from 0.04 (Mar 24) to 0.05, marking an increase of 0.01.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 2. It has increased from 0.04 (Mar 24) to 0.06, marking an increase of 0.02.
• For PBDIT Margin (%), as of Mar 25, the value is 11.02. This value is within the healthy range. It has decreased from 13.51 (Mar 24) to 11.02, marking a decrease of 2.49.
• For PBIT Margin (%), as of Mar 25, the value is 4.48. This value is below the healthy minimum of 10. It has decreased from 6.12 (Mar 24) to 4.48, marking a decrease of 1.64.
• For PBT Margin (%), as of Mar 25, the value is 3.76. This value is below the healthy minimum of 10. It has increased from 2.75 (Mar 24) to 3.76, marking an increase of 1.01.
• For Net Profit Margin (%), as of Mar 25, the value is 2.50. This value is below the healthy minimum of 5. It has increased from 2.04 (Mar 24) to 2.50, marking an increase of 0.46.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.61. This value is below the healthy minimum of 8. It has increased from 2.04 (Mar 24) to 2.61, marking an increase of 0.57.
• For Return on Networth / Equity (%), as of Mar 25, the value is 3.75. This value is below the healthy minimum of 15. It has increased from 3.61 (Mar 24) to 3.75, marking an increase of 0.14.
• For Return on Capital Employeed (%), as of Mar 25, the value is 4.85. This value is below the healthy minimum of 10. It has decreased from 6.92 (Mar 24) to 4.85, marking a decrease of 2.07.
• For Return On Assets (%), as of Mar 25, the value is 2.15. This value is below the healthy minimum of 5. It has increased from 1.45 (Mar 24) to 2.15, marking an increase of 0.70.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.06 (Mar 24) to 0.00, marking a decrease of 0.06.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.10 (Mar 24) to 0.00, marking a decrease of 0.10.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.83. It has increased from 0.71 (Mar 24) to 0.83, marking an increase of 0.12.
• For Current Ratio (X), as of Mar 25, the value is 2.15. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 2.15, marking an increase of 0.75.
• For Quick Ratio (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has increased from 1.40 (Mar 24) to 1.90, marking an increase of 0.50.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 26.84. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 26.84, marking an increase of 26.84.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 81.17. This value exceeds the healthy maximum of 50. It has decreased from 121.71 (Mar 24) to 81.17, marking a decrease of 40.54.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 23.13. This value is within the healthy range. It has decreased from 26.43 (Mar 24) to 23.13, marking a decrease of 3.30.
• For Earning Retention Ratio (%), as of Mar 25, the value is 18.83. This value is below the healthy minimum of 40. It has increased from -21.71 (Mar 24) to 18.83, marking an increase of 40.54.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 76.87. This value exceeds the healthy maximum of 70. It has increased from 73.57 (Mar 24) to 76.87, marking an increase of 3.30.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 15.39. This value is within the healthy range. It has increased from 3.72 (Mar 24) to 15.39, marking an increase of 11.67.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.50. This value is within the healthy range. It has increased from 1.49 (Mar 24) to 4.50, marking an increase of 3.01.
• For Enterprise Value (Cr.), as of Mar 25, the value is 947.72. It has decreased from 2,066.51 (Mar 24) to 947.72, marking a decrease of 1,118.79.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.72. This value exceeds the healthy maximum of 3. It has decreased from 9.72 (Mar 24) to 3.72, marking a decrease of 6.00.
• For EV / EBITDA (X), as of Mar 25, the value is 33.70. This value exceeds the healthy maximum of 15. It has decreased from 71.95 (Mar 24) to 33.70, marking a decrease of 38.25.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.00. This value exceeds the healthy maximum of 3. It has decreased from 9.89 (Mar 24) to 4.00, marking a decrease of 5.89.
• For Retention Ratios (%), as of Mar 25, the value is 18.82. This value is below the healthy minimum of 30. It has increased from -21.71 (Mar 24) to 18.82, marking an increase of 40.53.
• For Price / BV (X), as of Mar 25, the value is 5.75. This value exceeds the healthy maximum of 3. It has decreased from 17.47 (Mar 24) to 5.75, marking a decrease of 11.72.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.00. This value exceeds the healthy maximum of 3. It has decreased from 9.89 (Mar 24) to 4.00, marking a decrease of 5.89.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness